Synovial Sarcoma News and Research

RSS

Routine next-generation sequencing can identify BRAF mutations in synovial sarcoma

A new case report was published in Oncotarget's Volume 14 on July 7, 2023, entitled, "Intrathoracic synovial sarcoma with BRAF V600E mutation."

18 Jul 2023

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

20 Jun 2023

Novel T cell receptor therapy shows early promise for treating solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

9 Jan 2023

Targeting the Notch pathway with gamma secretase inhibitor improves outcomes in patients with rare cancers

Significant improvement in progression-free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumors, which are benign, but locally aggressive and invasive soft tissue tumors.

12 Sep 2022

Scientists develop new way to attack synovial sarcoma using an investigational drug

Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma -; a rare tumor of soft tissues, such as ligaments and muscles -; using an investigational drug that triggers cell death.

31 May 2022

Study generates a picture of the myocardial transcriptional landscape of COVID-19

Researchers profiled cardiac tissue transcriptomes of COVID-19 patients.

5 Apr 2022

New research sheds light on the origins of synovial sarcoma

A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and spreads.

3 Jun 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

3D structural model of BAF complex modifies DNA architecture, provides clues on cancer

Scientists have created an unprecedented 3-dimensional structural model of a key molecular "machine" known as the BAF complex, which modifies DNA architecture and is frequently mutated in cancer and some other diseases.

14 Oct 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

Scientists pinpoint protein that plays key role in synovial sarcoma tumors

Researchers have pinpointed a protein that plays a key role in a type of rare cancer often leading to tumours around joints and tendons, according to new findings in eLife.

27 Nov 2018

Potential new therapeutic approach developed for synovial sarcoma

Scientists have developed a potential new therapeutic approach for synovial sarcoma, one of the most common soft-tissue cancers in teenagers and young adults.

20 Nov 2018

Scientists receive critical funding to study treatments for three deadly cancers

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer.

17 Oct 2017

Early study of experimental vaccine shows escalating immune response in patients with sarcoma

The critical component of an experimental vaccine led to an escalating immune response in patients with sarcoma, an indicator of its potential anti-cancer effects.

2 Jun 2017

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Sarcomas- cancers of the connective tissues like muscles, joints, fat and bone -; come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.

3 May 2017

Houston Methodist researcher receives $4 million to create triple negative breast cancer immunotherapy

Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer.

13 Oct 2016

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014